                         SEQUENCE LISTING

<110>  TARIX PHARMACEUTICALS LTD.
 
<120>  COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES

<130>  2009912-0077

<140>  PCT/US2013/046429
<141>  2013-06-18

<150>  61/660,888
<151>  2012-06-18

<150>  61/720,296
<151>  2012-10-30

<160>  24    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  1

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<400>  2

Asp Arg Xaa Tyr Ile His Pro 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  homoserine

<400>  3

Asp Arg Val Xaa Ile His Cys 
1               5           


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  4

Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile 
1               5                   10          


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Any amino acid or dicarboxylic acid; Asp, Glu, Asn, Acpc 
       (1-aminocyclopentane carboxylic acid), Ala, Me2Gly 
       (N,N-dimethylglycine), Pro, Bet (betaine), Glu, Gly, Asp, Sar 
       (sarcosine) or Suc (succinic acid)

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Arg, Lys, Ala, Cit (citrulline), Orn (ornithine), acetylated Ser,
       Sar, D-Arg or D-Lys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Val, Ala, Leu, Nle (norleucine), Ile, Gly, Lys, Pro, HydroxyPro 
       (hydroxyproline), Aib (2-aminoisobutyric acid), Acpc or Tyr

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr, Tyr(PO3), Thr, Ser, homoSer (homoserine), azaTyr 
       (aza-alpha1-homo-L-tyrosine) or Ala

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Ile, Ala, Leu, norLeu, Val or Gly

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  His, Arg or 6-NH2-Phe (6-aminophenylalaine)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Cys, Pro or Ala

<400>  5

Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  6

Asp Arg Val Ser Ile His Cys 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Pro or Cys

<400>  7

Asp Arg Val Xaa Ile His Xaa 
1               5           


<210>  8
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Pro or Cys

<400>  8

Asp Arg Xaa Xaa Ile His Xaa Phe His Leu 
1               5                   10  


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Pro or Cys

<400>  9

Asp Arg Xaa Xaa Ile His Xaa Phe 
1               5               


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  2,6-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Pro or Cys

<400>  10

Arg Xaa Xaa Ile His Xaa Phe 
1               5           


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (2)..(5)
<223>  2,5-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Pro or Cys

<400>  11

Xaa Xaa Ile His Xaa Phe 
1               5       


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Pro or Cys

<400>  12

Asp Arg Xaa Xaa Ile His Xaa 
1               5           


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Pro or Cys

<400>  13

Asp Arg Xaa Xaa Ile His Xaa Phe His 
1               5                   


<210>  14
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Any amino acid, but typically a negatively-charged amino acid 
       such as Glu or Asp

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Any positively-charged amino acid such as Arg or Lys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Any aliphatic amino acid, such as Leu, Ile or Val

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-stereoisomer or L-stereoisomer

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Abu (2-aminobutyric acid), Ala, Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Any aliphatic amino acid, such as Leu, Ile or Val

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  His

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  His

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-stereoisomer or L-stereoisomer

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Abu (2-aminobutyric acid), Ala, Pro or Cys

<400>  14

Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5           


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Abu (2-aminobutyric acid)

<400>  15

Asp Arg Val Xaa Ile His Ala 
1               5           


<210>  16
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  16

Asp Arg Val Ala Ile His Ala 
1               5           


<210>  17
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Any amino acid, but typically a negatively charged amino acid 
       such as Glu or Asp

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Any positively charged amino acid such as Arg or Lys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-stereoisomer or L-stereoisomer

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Abu (2-aminobutyric acid), Ala, Tyr or Ser

<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Any aliphatic amino acid, such as Leu, Nle, Ile or Val

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  His

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-stereoisomer or L-stereoisomer

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Abu (2-aminobutyric acid), Ala, Pro or Cys

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Any amino acid other than Pro, typically Phe or Ile

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  His

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Any aliphatic residue, such as Ile, Val or Leu

<400>  17

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Abu (2-aminobutyric acid)

<400>  18

Asp Arg Xaa Xaa Ile His Ala 
1               5           


<210>  19
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<400>  19

Asp Arg Xaa Ala Ile His Ala 
1               5           


<210>  20
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Abu (2-aminobutyric acid)

<400>  20

Asp Arg Xaa Xaa Ile His Ala Ile 
1               5               


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Nle

<400>  21

Asp Arg Xaa Ala Ile His Ala Ile 
1               5               


<210>  22
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(7)
<223>  4,7-cyclization including thioether cyclization

<400>  22

Asp Arg Val Ser Ile His Cys 
1               5           


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  23

Asp Arg Val Tyr Ile His Pro Phe His 
1               5                   


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide

<400>  24

Ala Arg Val Tyr Ile His Pro 
1               5           


